Medpacto, Inc. (South Korea)

MedPacto, Inc. is a Seoul, South Korea-based firm founded in 2013. The company operates in the healthcare and manufacturing and industrials industries. It has a workforce of 101-500 employees. MedPacto, Inc. specializes in drug discovery and development, with a focus on therapeutics for cancer and autoimmune diseases in South Korea. The company is currently working on several drug candidates, including ME-1601mAb, MS-1601A, and vactosertib, which target specific proteins associated with cancers and autoimmune diseases. Vactosertib, in particular, has shown promise in improving the response to various therapies by inhibiting immune-suppressive activity and suppressing cancer stem cell resistance mechanisms. MedPacto is also developing MP005A, an antibody therapeutics targeting BAG2 protein, and MP005D, a diagnostic kit for detecting BAG2 genes. The company is dedicated to genome-based drug discovery and aims to develop innovative therapies for challenging diseases like cancer. MedPacto is currently conducting combination trials with Vactosertib for various cancer indications. Vactosertib is an orally bioavailable small-molecule inhibitor currently in phase Ⅱ clinical trials with global pharmaceutical companies. It works by inhibiting the TGF-β pathway, which is known to promote cancer cell metastasis and proliferation by affecting the tumor microenvironment.